LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 243

Search options

  1. Article ; Online: The Case for Therapeutic-Intensity Anticoagulation in Patients with COVID-19-Associated Moderate Illness.

    Cuker, Adam

    Seminars in thrombosis and hemostasis

    2022  

    Language English
    Publishing date 2022-09-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 196901-8
    ISSN 1098-9064 ; 0094-6176
    ISSN (online) 1098-9064
    ISSN 0094-6176
    DOI 10.1055/s-0042-1756709
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Thrombosis with thrombocytopenia syndrome after COVID-19 vaccination.

    Cuker, Adam

    Clinical advances in hematology & oncology : H&O

    2021  Volume 19, Issue 7, Page(s) 446–449

    MeSH term(s) COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; Humans ; SARS-CoV-2 ; Thrombocytopenia/epidemiology ; Thrombocytopenia/etiology ; Thrombosis/epidemiology ; Thrombosis/etiology
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2021-07-08
    Publishing country United States
    Document type Interview
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: The Case for Therapeutic-Intensity Anticoagulation in Patients with COVID-19-Associated Moderate Illness

    Cuker, Adam

    Seminars in Thrombosis and Hemostasis

    (Maintaining Hemostasis and Preventing Thrombosis in COVID-19—Part IV)

    2022  Volume 49, Issue 01, Page(s) 76–78

    Series title Maintaining Hemostasis and Preventing Thrombosis in COVID-19—Part IV
    Language English
    Publishing date 2022-09-29
    Publisher Thieme Medical Publishers, Inc.
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 196901-8
    ISSN 1098-9064 ; 0094-6176
    ISSN (online) 1098-9064
    ISSN 0094-6176
    DOI 10.1055/s-0042-1756709
    Database Thieme publisher's database

    More links

    Kategorien

  4. Article ; Online: Development and use of clinical practice guidelines on venous thromboembolism.

    Cuker, Adam

    Translational research : the journal of laboratory and clinical medicine

    2020  Volume 225, Page(s) 1–8

    Abstract: Venous thromboembolism (VTE) is a common disorder associated with substantial morbidity and mortality. It may be encountered by clinicians in virtually all medical specialties and healthcare settings. A large number of clinical practice guidelines (CPGs) ...

    Abstract Venous thromboembolism (VTE) is a common disorder associated with substantial morbidity and mortality. It may be encountered by clinicians in virtually all medical specialties and healthcare settings. A large number of clinical practice guidelines (CPGs) on VTE have been published in recent years to support clinicians in delivering high-quality care for the prevention, diagnosis, and management of VTE. Essential elements of CPGs include a guideline panel composed of content experts from multiple disciplines, methodologists, and representatives from key affected groups; a systematic review of evidence; consideration of patient subgroups and patient values and preferences; management of conflicts of interest; an explanation of the relationship between alternative care options and health outcomes; and rating of the quality of evidence and strength of recommendations. These elements enhance the transparency and trustworthiness of CPGs and set them apart from other types of clinical guidance documents. The objectives of this narrative review are to summarize methods used to develop CPGs and to provide guidance to end-users on how to interpret recommendations and apply them in clinical practice. While much of the content of this review applies to CPGs in general, irrespective of disease focus, a number of examples specific to VTE are included.
    MeSH term(s) Humans ; Practice Guidelines as Topic ; Venous Thromboembolism/therapy
    Language English
    Publishing date 2020-05-17
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2246684-8
    ISSN 1878-1810 ; 1532-6543 ; 1931-5244
    ISSN (online) 1878-1810 ; 1532-6543
    ISSN 1931-5244
    DOI 10.1016/j.trsl.2020.05.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: TPO-RAs and ITP remission: cause or coincidence?

    Sanfilippo, Kristen M / Cuker, Adam

    Blood

    2023  Volume 141, Issue 23, Page(s) 2790–2791

    MeSH term(s) Humans ; Prospective Studies ; Purpura, Thrombocytopenic, Idiopathic/therapy ; Receptors, Thrombopoietin
    Chemical Substances Receptors, Thrombopoietin
    Language English
    Publishing date 2023-05-23
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2023020243
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Immune thrombocytopenia: vaccination does not equal causation.

    Pishko, Allyson / Cuker, Adam

    Haematologica

    2022  Volume 107, Issue 5, Page(s) 1020–1021

    MeSH term(s) Humans ; Purpura, Thrombocytopenic, Idiopathic/etiology ; Thrombocytopenia/etiology ; Vaccination/adverse effects
    Language English
    Publishing date 2022-05-01
    Publishing country Italy
    Document type Journal Article ; Comment
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2021.279727
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Early-onset heparin-induced thrombocytopenia after cardiac surgery: Should we lose sleep?

    Pishko, Allyson / Cuker, Adam

    Journal of thrombosis and haemostasis : JTH

    2022  Volume 20, Issue 11, Page(s) 2491–2493

    MeSH term(s) Humans ; Thrombocytopenia/chemically induced ; Thrombocytopenia/diagnosis ; Heparin/adverse effects ; Cardiac Surgical Procedures/adverse effects ; Sleep ; Anticoagulants/adverse effects
    Chemical Substances Heparin (9005-49-6) ; Anticoagulants
    Language English
    Publishing date 2022-10-18
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2112661-6
    ISSN 1538-7836 ; 1538-7933
    ISSN (online) 1538-7836
    ISSN 1538-7933
    DOI 10.1111/jth.15840
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices.

    Cuker, Adam

    American journal of hematology

    2018  Volume 93, Issue 6, Page(s) 816–823

    Abstract: In patients with immune thrombocytopenia who do not adequately respond to first-line therapy, there is no clear consensus on which second-line therapy to initiate and when. This situation leads to suboptimal approaches, including prolonged exposure to ... ...

    Abstract In patients with immune thrombocytopenia who do not adequately respond to first-line therapy, there is no clear consensus on which second-line therapy to initiate and when. This situation leads to suboptimal approaches, including prolonged exposure to treatments that are not intended for long-term use (eg, corticosteroids) and overuse of off-label therapies (eg, rituximab) while approved, more efficacious options exist. These approaches may not only fail to address symptoms and burden of disease, but may also worsen health-related quality of life. A better understanding of available second-line treatments may ensure best use of therapeutic options and thereby optimize patient outcomes.
    MeSH term(s) Adrenal Cortex Hormones/therapeutic use ; Humans ; Purpura, Thrombocytopenic, Idiopathic/drug therapy ; Receptors, Thrombopoietin/agonists ; Remission Induction/methods ; Rituximab/therapeutic use ; Splenectomy ; Therapeutics/adverse effects ; Therapeutics/methods ; Therapeutics/standards
    Chemical Substances Adrenal Cortex Hormones ; Receptors, Thrombopoietin ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2018-04-15
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.25092
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Thrombocytopenia and liver disease: pathophysiology and periprocedural management.

    Lim, Hana I / Cuker, Adam

    Hematology. American Society of Hematology. Education Program

    2022  Volume 2022, Issue 1, Page(s) 296–302

    Abstract: Abnormal bleeding in patients with liver disease may result from elevated portal pressure and varix formation, reduced hepatic synthesis of coagulation proteins, qualitative platelet dysfunction, and/or thrombocytopenia. Major mechanisms of ... ...

    Abstract Abnormal bleeding in patients with liver disease may result from elevated portal pressure and varix formation, reduced hepatic synthesis of coagulation proteins, qualitative platelet dysfunction, and/or thrombocytopenia. Major mechanisms of thrombocytopenia in liver disease include splenic sequestration and impaired platelet production due to reduced thrombopoietin production. Alcohol and certain viruses may induce marrow suppression. Immune thrombocytopenia (ITP) may co-occur in patients with liver disease, particularly those with autoimmune liver disease or chronic hepatitis C. Drugs used for the treatment of liver disease or its complications, such as interferon, immunosuppressants, and antibiotics, may cause thrombocytopenia. Periprocedural management of thrombocytopenia of liver disease depends on both individual patient characteristics and the bleeding risk of the procedure. Patients with a platelet count higher than or equal to 50 000/µL and those requiring low-risk procedures rarely require platelet-directed therapy. For those with a platelet count below 50 000/µL who require a high-risk procedure, platelet-directed therapy should be considered, especially if the patient has other risk factors for bleeding, such as abnormal bleeding with past hemostatic challenges. We often target a platelet count higher than or equal to 50 000/µL in such patients. If the procedure is elective, we prefer treatment with a thrombopoietin receptor agonist; if it is urgent, we use platelet transfusion. In high-risk patients who have an inadequate response to or are otherwise unable to receive these therapies, other strategies may be considered, such as a trial of empiric ITP therapy, spleen-directed therapy, or transjugular intrahepatic portosystemic shunt placement.
    Language English
    Publishing date 2022-12-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2084287-9
    ISSN 1520-4383 ; 1520-4391
    ISSN (online) 1520-4383
    ISSN 1520-4391
    DOI 10.1182/hematology.2022000408
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Heparin-induced thrombocytopenia and cardiovascular surgery.

    Pishko, Allyson M / Cuker, Adam

    Hematology. American Society of Hematology. Education Program

    2022  Volume 2021, Issue 1, Page(s) 536–544

    Abstract: Clinicians generally counsel patients with a history of heparin-induced thrombocytopenia (HIT) to avoid heparin products lifelong. Although there are now many alternative (nonheparin) anticoagulants available, heparin avoidance remains challenging for ... ...

    Abstract Clinicians generally counsel patients with a history of heparin-induced thrombocytopenia (HIT) to avoid heparin products lifelong. Although there are now many alternative (nonheparin) anticoagulants available, heparin avoidance remains challenging for cardiac surgery. Heparin is often preferred in the cardiac surgery setting based on the vast experience with the agent, ease of monitoring, and reversibility. To "clear" a patient with a history of HIT for cardiac surgery, hematologists must first confirm the diagnosis of HIT, which can be challenging due to the ubiquity of heparin exposure and frequency of thrombocytopenia in patients in the cardiac intensive care unit. Next, the "phase of HIT" (acute HIT, subacute HIT A/B, or remote HIT) should be established based on platelet count, immunoassay for antibodies to platelet factor 4/heparin complexes, and a functional assay (eg, serotonin release assay). As long as the HIT functional assay remains positive (acute HIT or subacute HIT A), cardiac surgery should be delayed if possible. If surgery cannot be delayed, an alternative anticoagulant (preferably bivalirudin) may be used. Alternatively, heparin may be used with either preoperative/intraoperative plasma exchange or together with a potent antiplatelet agent. The optimal strategy among these options is not known, and the choice depends on institutional experience and availability of alternative anticoagulants. In the later phases of HIT (subacute HIT B or remote HIT), brief intraoperative exposure to heparin followed by an alternative anticoagulant as needed in the postoperative setting is recommended.
    Language English
    Publishing date 2022-01-05
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2084287-9
    ISSN 1520-4383 ; 1520-4391
    ISSN (online) 1520-4383
    ISSN 1520-4391
    DOI 10.1182/hematology.2021000289
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top